Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Strengthens Clinical Development Organization with Three Management Appointments

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.

MorphoSys AG has announced that it has completed the expansion of its senior clinical development team by appointing Dr. Gabriele Elbl as Head of Regulatory Affairs, Dr. Ludger Langer as Head of Clinical Operations and Project Management and most recently Dr. Steffen Heeger as Head of Clinical Research.

Gabriele Elbl joined MorphoSys after working for more than 20 years in small and large pharmaceutical companies. During this time she gained a deep understanding of all regulatory aspects of product development, both for the US and the EU.

Dr. Elbl has extensive experience of development programs for biologics through interactions with both the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Most recently she held the position of Senior Vice President, Regulatory Affairs at Wilex AG, Munich.

Prior to that she worked as a Scientific Administrator at the EMA, London, and served as Head of Pharmaceutical Department at Sanofi Winthrop in Munich. Dr. Elbl studied pharmacy and received a PhD in Pharmaceutical Biology from the Ludwig-Maximilian-University, Munich.

Ludger Langer joined MorphoSys from PRA International. He brings almost 20 years of clinical operations and project management experience to MorphoSys. Dr. Langer held several positions of increasing seniority in Clinical Operations and Project Management with a focus on planning and execution of multiregional clinical trials.

Prior to joining MorphoSys, Dr. Langer was Vice President, Clinical Operations, Europe, Asia-Pacific and Africa at PRA International. Dr. Langer studied pharmacy and received a PhD from the Goethe University, Frankfurt/Main.

Steffen Heeger is an oncologist with deep experience in oncology drug development from his past ten years at Merck Serono, where he was Head of Medical Affairs and where he led the Global Clinical Development Team for Erbitux®. Dr. Heeger studied Medicine in Freiburg, Heidelberg and Mannheim and continued his medical training at the Clinic of Hematology/Oncology of the University of Heidelberg.

During this time he was also a scientist at the German Cancer Research Center (DKFZ) in Heidelberg where he worked on the development of antibody conjugates. He received a PhD in Medicine from the University of Heidelberg.

"We are very pleased to have gained three outstanding individuals for these key positions within the MorphoSys development organization," explained Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "The appointment of Gabriele Elbl and Ludger Langer earlier this year and most recently Steffen Heeger already had a significant impact on our development capabilities and underscores our strong commitment to the further expansion, development and commercialization of our proprietary drug portfolio."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Reports Promising Pre-clinical Data for MOR202
Combination studies to be presented at Annual Meeting of the American Society of Clinical Oncology.
Tuesday, May 24, 2011
MorphoSys Announces Clinical Milestone from Strategic Alliance
The announcement represents the second HuCAL-derived antibody to achieve this stage during the course of 2010.
Friday, July 02, 2010
MorphoSys Announces Clinical Milestone from Centocor Ortho Biotech
The milestone marks the initiation of a phase 1 clinical trial of a HuCAL-derived antibody.
Thursday, June 24, 2010
AbD Serotec Enters New Growth Area
Recombinant anti-idiotype antibodies as important research and drug development tools.
Tuesday, May 18, 2010
MorphoSys and WACKER Expand Cooperation to Use WACKER's ESETEC® Technology
MorphoSys will now be able to use the WACKER technology for the production of antigen material.
Thursday, February 04, 2010
MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
Company's MOR103 program is a fully human HuCAL antibody directed against GM-CSF being developed for inflammatory diseases.
Thursday, January 21, 2010
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Germany's Paul-Ehrlich-Institute approves clinical trial in rheumatoid arthritis patients.
Monday, November 16, 2009
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Antibody Therapies against Hospital-Acquired Infections
Daiichi Sankyo becomes MorphoSys's first collaborator for HuCAL PLATINUM®-based drug discovery in infectious diseases.
Tuesday, October 20, 2009
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
Companies announce filling of the documentation to initiate a Phase 1 clinical trial with eighth HuCAL antibody.
Tuesday, September 08, 2009
MorphoSys and the University of Melbourne File new Patent Applications in MOR103 Program
MOR103 HuCAL antibody against human GM-CSF is currently in development for the treatment of rheumatoid arthritis.
Friday, July 03, 2009
MorphoSys Strengthens Patent Position on its Core Technologies in Japan
Patent covers CysDisplay® proprietary screening technology, a component of MorphoSys's proprietary HuCAL platform.
Thursday, June 18, 2009
MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
The agreement grants Schering-Plough continued access to MorphoSys's antibody library HuCAL GOLD at its research site in Palo Alto, California.
Tuesday, June 16, 2009
Shionogi Extends Research Partnership with MorphoSys
Shionogi extends its current license agreement covering the use of MorphoSys's HuCAL technology in drug discovery, for three additional years.
Monday, September 29, 2008
MorphoSys Nominates First Pre-Development Program in Antibody Collaboration
MorphoSys announced today that it has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis.
Thursday, September 25, 2008
MorphoSys Announces Publication of First MOR103 Data
MorphoSys announced today the publication of a first data package for its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF, in the journal "Molecular Immunology".
Wednesday, September 03, 2008
Scientific News
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
Drug Design Strategy to Improve Breast Cancer Treatment
Scientists develop novel structure-based drug design strategy aimed at altering the basic landscape of hormone-driven breast cancer treatment.
`Molecular Commando’ Identified to Tackle Hypoxia Pathway
Scientists identify 'molecular commando' that can activate hypoxic response, which helps combat a number of conditions.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Two Antibiotics Fight Bacteria Differently Than Thought
Researchers discover that two widely prescribed antibiotics may fight bacteria differently than previously thought.
Drug Target for Gastrointestinal Stromal Tumors Identified
Researchers show the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!